Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva) and Fulvestrant (Faslodex) Versus Erlotinib (Tarceva) Alone in Advanced Non-Small Cell Lung Cancer Patients

Trial Profile

A Randomized Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva) and Fulvestrant (Faslodex) Versus Erlotinib (Tarceva) Alone in Advanced Non-Small Cell Lung Cancer Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Fulvestrant (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jan 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 05 Jan 2018 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top